Efficacy and Safety of Methoxyflurane (Penthrox) for the Treatment of Acute Pain in Minor Trauma
Launched by MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED · Aug 18, 2011
Trial Information
Current as of July 25, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients 12 years of age or older who are able to give written informed consent or who are accompanied by a parent(s)/legal guardian able to provide written informed consent on their behalf.
- • Evidence of signed and dated informed consent document(s) indicating that the patient (and/or a parent/legal guardian) has been informed of all pertinent aspects of the study.
- • Pain Score ≥ 4 to ≤ 7 as measured using Numerical Rating Scale (NRS) at the time of admission, due to minor trauma.
- Exclusion Criteria:
- • Life-threatening condition requiring immediate admission in the Operating Room or Intensive Care Unit.
- • Presence of any other clinical condition(s) that may, in the opinion of the investigator, impact on the patient's ability to participate in the study, or on the study results, including history of head injury and/or altered consciousness.
- • Unable to provide written informed consent.
- • Known pregnancy or lactation
- • Acute intoxication with drugs or alcohol, based on the judgement of the attending physician.
- • Treatment with any analgesic agent within 5 hours prior to presentation to ED (except diclofenac sodium which is prohibited within 8 hours prior to presentation to ED).
- • Current ongoing use of analgesics for chronic pain.
- • Use of an investigational product within one month prior to presentation to ED.
- • Known personal or familial hypersensitivity to fluorinated anaesthetics.
- • Known personal or familial history of malignant hyperthermia.
- • Clinically significant respiratory depression.
- • Use of methoxyflurane in the previous 4 weeks.
- • Known pre-existing clinically significant renal or hepatic impairment according to the judgement of the clinician.
- • Clinically significant cardiovascular instability.
About Medical Developments International Limited
Medical Developments International Limited is a forward-thinking healthcare company specializing in the development and commercialization of innovative medical products and therapies. With a strong focus on enhancing patient outcomes, the company leverages its expertise in drug delivery systems and medical devices to address unmet clinical needs. Committed to rigorous research and development, Medical Developments International Limited collaborates with healthcare professionals and regulatory bodies to ensure the efficacy and safety of its products. The company aims to contribute to the advancement of medical science and improve the quality of care for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Colchester, , United Kingdom
Middlesbrough, , United Kingdom
Newcastle Upon Tyne, , United Kingdom
Birmingham, , United Kingdom
Barnsley, , United Kingdom
Nottingham, , United Kingdom
Patients applied
Trial Officials
Frank M Coffey
Principal Investigator
Nottingham University Hospitals, Queen's Medical Centre Campus
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials